GLP-3 RT + Cagri
Combination Metabolic Research Compound - GLP-3 RT (10mg) co-formulated with Cagrilintide (2mg) in one vial.
A co-formulated research preparation pairing the triple-receptor compound GLP-3 RT with the amylin analogue Cagrilintide, prepared for laboratories studying incretin-class and amylin-class receptor signaling in combination.
Combination preparations like this one exist so incretin-class and amylin-class signaling can be examined from one reference rather than two separately reconstituted compounds. The lot certificate characterizes the preparation as supplied; the two components are not reported as separate figures.
GLP-3 RT + Cagri specifications
- Molecular formula
- Co-formulated blend
- Sequence
- GLP-3 RT 10mg + Cagrilintide 2mg
- Residues
- GLP-3 RT 10mg + Cagrilintide 2mg
- Presentation
- Lyophilized powder
- Documented purity
- 99.87% by HPLC
- Available sizes
- 10mg / 2mg ($90)
- Archived COA lots
- 1
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Incretin-receptor engagement - The GLP-3 RT component is studied across the GLP-1, GIP and glucagon receptor families in in-vitro assays.
- Amylin-receptor engagement - The Cagrilintide component is characterized at amylin and calcitonin receptors.
Reported mechanisms in the literature
- GLP-3 RT component - Studied across the GLP-1, GIP and glucagon receptor families in in-vitro cAMP assays. (Coskun et al.)
- Cagrilintide component - Characterized at amylin and calcitonin receptors, allowing combined incretin and amylin signaling to be studied in one preparation. (Preclinical literature)
What GLP-3 RT + Cagri is researched for
- Incretin + amylin - Studied for combined incretin-class and amylin-class receptor engagement from a single preparation. (Combination research)
- Combination selectivity - Investigated against single-component comparators in in-vitro receptor panels. (Preclinical literature)
GLP-3 RT + Cagri certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| VG8ZGB | 14 Oct 2026 | 10mg / 2mg | Freedom Diagnostics | 99.87% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on GLP-3 RT + Cagri
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
GLP-3 RT + Cagri frequently asked questions
What is in the vial?
10mg of GLP-3 RT and 2mg of Cagrilintide, co-formulated as one lyophilized preparation.
Is it approved for human use?
No. It is a research material only, supplied for in-vitro laboratory study.
How is it documented?
Each lot ships with its Certificate of Analysis, which reports the preparation's identity and purity.
Documented to 99.87% purity by HPLC · third-party COA every lot · from $90 · For laboratory research use only.
Related Metabolic compounds
- GLP-1 S - Single-agonist GLP-1 research compound.
- GLP-3 RT - Triple-receptor GLP research compound (GLP-1/GIP/glucagon class).
- GLP-2 TZ - Dual GIP/GLP-1 receptor co-agonist studied in glucose-handling and energy-balance research.
- Cagrilintide - Acylated amylin analogue studied for amylin and calcitonin receptor signaling.
- 5-Amino-1MQ - Small-molecule NNMT inhibitor studied in metabolism research.
- MOTS-c - Mitochondrial-derived peptide studied for metabolic regulation.